Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses the launch of the first rituximab biosimilar in the United States.
Transcript
Yeah, it's a good question. So the rituximab biosimilar is very exciting, to be launched, the first one is just launched. And I think it's going to have a significant impact in oncology care. But I'm not sure it's going to be immediate.
Part of that is really the 10% pricing strategy that they came out with. I think it's safe to say that most providers and health system perspectives are hoping and anticipating at least a 15% to 30% discount based off of the originator biologic, which is what we've seen pretty consistently with other biosimilars.
So the 10% is hard to gauge because what you have to think about from a health system perspective is there is a significant cost of change. So for any new therapeutic, when you evaluate a drug for a [pharmacy and therapeutics, P and T] committee, and it becomes approved, there's a whole downstream effect of how to make it implemented within the health system.
So that includes IT updates to order sets, procurement and storage considerations, administration considerations, and then of course, the finance piece of doing prior authorizations and making sure the products are covered. So there's a whole downstream effect that becomes the cost of change that needs to be considered.
I don't think the 10% is going to be received with excitement from the provider lens, but I think it's going be interesting to see when additional competitors come to the market in this space, what that impact will be.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.